Systemic lupus erythematosus (SLE) patients have lower bone mineral density (BMD) compared with healthy individuals because of general, genetic, disease and medication-related factors. The disturbance of the receptor activator of nuclear factor-κB ligand (RANKL)/osteoprotegerin (OPG) ratio has been reported to be associated with low BMD in many disorders in adults and children alike.
Objectives
The objectives of this study were (i) to assess serum OPG, RANKL and RANKL/OPG ratio levels in SLE children and controls, (ii) to determine whether the cumulative glucocorticoid (CGCS) dose had any effect on the concentration of serum RANKL, OPG and RANKL/OPG ratio, and (iii) to determine the relation of these parameters to BMD.
Methods
We evaluated 50 SLE children and 50 age- and sex-matched healthy controls. RANKL and OPG were assessed in serum and compared between patients and controls. For SLE patients, a univariate followed by multivariable analysis were carried out to detect the possible predictors of the changes in RANKL, OPG and RANKL/OPG ratio levels. Lumbar BMD for all patients was assessed by dual-energy X-ray absorptiometry (DXA) scan and then correlated to different probable correlated factors.
Results
RANKL, OPG and RANKL/OPG ratio were significantly higher in SLE patients (p ≤ 0.001). Univariate analysis showed significant correlations of RANKL with CGCS (p ≤ 0.001) and with DXA scan z-score (p = 0.007): OPG was significantly correlated to Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score (p = 0.001) and anti-double-stranded DNA (p = 0.001), whereas RANKL/OPG was significantly correlated to duration of illness and DXA z-score (p = 0.002). The multivariable analysis showed that DXA z-score was an independent predictor of RANKL and RANKL/OPG ratio (p = 0.019 and 0.008, respectively), whereas SLEDAI score was an independent predictor of OPG levels. BMD was negatively correlated to disease duration (p = 0.008) and CGCS dose (p = 0.015), but no significant correlation has been found between BMD and cumulative SLEDAI score (p = 0.29).
Conclusions
Serum RANKL/OPG ratio is elevated in Egyptian children with SLE and is considered a risk factor for reduced bone mass in these children. Other risk factors for low BMD include high CGCS dose and disease duration, supporting that osteoporosis in SLE is multifactorial.
LeeCRamsey-GoldmanR. Bone health and systemic lupus erythematosus. Curr Rheumatol Rep2005; 7: 482–489.
2.
AleleJDKamenDL. The importance of inflammation and vitamin D status in SLE-associated osteoporosis. Autoimmun Rev2010; 9: 137–139.
3.
WalshNCCrottiTNGoldringSRGravalleseEM. Rheumatic diseases: The effects of inflammation on bone. Immunol Rev2005; 208: 228–251.
4.
PanopalisPYazdanyJ. Bone health in systemic lupus erythematosus. Curr Rheumatol Rep2009; 11: 177–184.
5.
AlkadyEARashadSMKhedrTMMossadEAbdel-WahabN. Early predictors of increased bone resorption in juvenile idiopathic arthritis: OPG/RANKL ratio, as a key regulator of bone metabolism. The Egyptian Rheumatologist2011; 33: 217–223.
6.
LienGUelandTGodangKSelvaagAMFørreOTFlatøB. Serum levels of osteoprotegerin and receptor activator of nuclear factor -κB ligand in children with early juvenile idiopathic arthritis: A 2-year prospective controlled study. Pediatr Rheumatol Online J2010; 8: 30.
7.
BuziFMaccarinelliGGuaragniB, et al.Serum osteoprotegerin and receptor activator of nuclear factors kB (RANKL) concentrations in normal children and in children with pubertal precocity, Turner's syndrome and rheumatoid arthritis. Clin Endocrinol (Oxf)2004; 60: 87–91.
8.
WasilewskaARybi-SzuminskaAZoch-ZwierzW. Serum RANKL, osteoprotegerin (OPG), and RANKL/OPG ratio in nephrotic children. Pediatr Nephrol2010; 25: 2067–2075.
9.
ReichardtHMTuckermannJPBauerASchützG. Molecular genetic dissection of glucocorticoid receptor function in vivo. Rheumatol2000; 59(suppl 2): ii1–ii5.
10.
HofbauerLCGoriFRiggsBL, et al.Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: Potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology1999; 140: 4382–4389.
11.
HochbergMC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1997; 40: 1725.
El-ZinyMAAl-TonbaryYASalamaOSBakrAAAl-MarsafawyHElsharkawyAA. Low turnover bone disease in Egyptian children with acute leukemia. Hematology2005; 10: 327–333.
14.
El-ZinyMAAl-TonbaryYASalamaOSBakrAAAl-MarsafawyHElsharkawyAA. Low bone mass in children with malignant lymphoma. Pediatr Hematol Oncol2007; 24: 577–585.
15.
BinkleyNBilezikianJPKendlerDL, et al.Official positions of the International Society for Clinical Densitometry and Executive Summary of the 2005 Position Development Conference. J Clin Densitom2006; 9: 4–14.
16.
ElmougyASarhanAHammadA, et al.Lupus nephritis in Egyptian children: A 16-year experience. J Nephrol2015; 28: 557–562.
17.
Carmona-FernandesDSantosMJPerpétuoIPFonsecaJECanhãoH. Soluble receptor activator of nuclear factor κB ligand/osteoprotegerin ratio is increased in systemic lupus erythematosus patients. Arthritis Res Ther2011; 13: R175.
18.
BostanciNIlgenliTEmingilG, et al.Gingival crevicular fluid levels of RANKL and OPG in periodontal diseases: Implications of their relative ratio. J Clin Periodontol2007; 34: 370–376.
19.
TsentidisCGourgiotisDKossivaL, et al.Higher levels of s-RANKL and osteoprotegerin in children and adolescents with type 1 diabetes mellitus may indicate increased osteoclast signaling and predisposition to lower bone mass: A multivariate cross-sectional analysis. Osteoporos Int2016; 27: 1631–1643.
20.
OzkayaOBuyanNBideciA, et al.Osteoprotegerin and RANKL serum levels and their relationship with serum ghrelin in children with chronic renal failure and on dialysis. Nephron Clin Pract2007; 105: 153–158.
21.
KwokSKShinYJKimHJ, et al.Circulating osteoprotegerin levels are elevated and correlated with antiphospholipid antibodies in patients with systemic lupus erythematosus. Lupus2009; 18: 133–138.
22.
GuptaRAggarwalASinhaS, et al.Urinary osteoprotegerin: A potential biomarker of lupus nephritis disease activity. Lupus2016; 25: 1230–1236.
23.
SasakiNKusanoEAndoY, et al.Changes in osteoprotegerin and markers of bone metabolism during glucocorticoid treatment in patients with chronic glomerulonephritis. Bone2002; 30: 853–858.
24.
SandalSRawatAGuptaA, et al.141 Soluble receptor activator of nuclear factor Κ b ligand (S RANK-L) levels in paediatric onset SLE. Lupus Sci Med2017; 4: A1–A227.
25.
SchoppetMSattlerAMSchaeferJRHerzumMMaischBHofbauerLC. Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab2003; 88: 1024–1028.
26.
ZiolkowskaMKurowskaMRadzikowskaA, et al.High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. Arthritis Rheum2002; 46: 1744–1753.
27.
KianiANJohnsonKChenC, et al.Urine osteoprotegerin and monocyte chemoattractant protein-1 in lupus nephritis. J Rheumatol2009; 36: 2224–2230.
28.
El-ShehabyADarweeshHEl-KhatibM, et al.Correlations of urinary biomarkers, TNF-like weak inducer of apoptosis (TWEAK), osteoprotegerin (OPG), monocyte chemoattractant protein-1 (MCP-1), and IL-8 with lupus nephritis. J Clin Immunol2011; 31: 848–856.
29.
KlimekESkalskaAKwaśny-KrochinB, et al.Differential associations of inflammatory and endothelial biomarkers with disease activity in rheumatoid arthritis of short duration. Mediators Inflamm2014; 2014: 681635.
30.
ŚwierkotJGruszeckaKMatuszewskaAWilandP. Assessment of the effect of methotrexate therapy on bone metabolism in patients with rheumatoid arthritis. Arch Immunol Ther Exp (Warsz)2015; 63: 397–404.
31.
ZannettinoACHoldingCADiamondP, et al.Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. J Cell Physiol2005; 204: 714–723.
32.
Collin-OsdobyPRotheLAndersonFNelsonMMaloneyWOsdobyP. Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem2001; 276: 20659–20672.
33.
Benito-MartinAUceroACZubiriI, et al.Osteoprotegerin in exosome-like vesicles from human cultured tubular cells and urine. PLoS One2013; 8: e72387.
34.
Montañez-BarragánAGómez-BarreraISanchez-NiñoMDUceroACGonzález-EspinozaLOrtizA. Osteoprotegerin and kidney disease. J Nephrol2014; 27: 607–617.
35.
BachrachLK. Dual energy X-ray absorptiometry (DEXA) measurements of bone density and body composition: Promise and pitfalls. J Pediatr Endocrinol Metab2000; 13(suppl 2): 983–988.
36.
TrapaniSCivininiRErminiMPaciEFalciniF. Osteoporosis in juvenile systemic lupus erythematosus: A longitudinal study on the effect of steroids on bone mineral density. Rheumatol Int1998; 18: 45–49.
37.
WaradyBDLindsleyCBRobinsonFGLukertBP. Effects of nutritional supplementation on bone mineral status of children with rheumatic diseases receiving corticosteroid therapy. J Rheumatol1994; 21: 530–535.
38.
Baker-LePainJCNakamuraMCShepherdJvon SchevenE. Assessment of bone remodeling in childhood-onset systemic lupus erythematosus. Rheumatology (Oxford)2010; 50: 611–619.
39.
CastroTCTerreriMTSzejnfeldVL, et al.Bone mineral density in juvenile systemic lupus erythematosus. Braz J Med Biol Res2002; 35: 1159–1163.
40.
AlsufyaniKAOrtiz-AlvarezOCabralDA, et al.Bone mineral density in children and adolescents with systemic lupus erythematosus, juvenile dermatomyositis, and systemic vasculitis: Relationship to disease duration, cumulative corticosteroid dose, calcium intake, and exercise. J Rheumatol2005; 32: 729–733.
41.
LillebyVLienGFrey FrøslieKHaugenMFlatøBFørreØ. Frequency of osteopenia in children and young adults with childhood-onset systemic lupus erythematosus. Arthritis Rheum2005; 52: 2051–2059.
42.
AbrahamsenBHjelmborgJVKostenuikP, et al.Circulating amounts of osteoprotegerin and RANK ligand: Genetic influence and relationship with BMD assessed in female twins. Bone2005; 6: 727–735.
43.
UelandTYndestadAØieE, et al.Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation2005; 111: 2461–2468.
44.
UemuraHYasuiTMiyataniY, et al.Circulating profiles of osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand in post-menopausal women. J Endocrinol Invest2008; 31: 163–168.
45.
KimJGKimJHLeeDO, et al.Changes in the serum levels of osteoprotegerin and soluble receptor activator for nuclear factor kappaB ligand after estrogen-progestogen therapy and their relationships with changes in bone mass in postmenopausal women. Menopause2008; 15: 357–362.
46.
Rouster-StevensKALangmanCBPriceHE, et al.RANKL: Osteoprotegerin ratio and bone mineral density in children with untreated juvenile dermatomyositis. Arthritis Rheum2007; 56: 977–983.
47.
SpellingPBonfáECaparboVFPereiraRM. Osteoprotegerin/RANKL system imbalance in active polyarticular-onset juvenile idiopathic arthritis: A bone damage biomarker?. Scand J Rheumatol2008; 37: 439–444.
48.
CoimbraIBCostallatLT. Bone mineral density in systemic lupus erythematosus and its relation to age at disease onset, plasmatic estradiol and immunosuppressive therapy. Joint Bone Spine2003; 70: 40–45.
49.
YijunZHuDShunleC, et al.The significance of the RANKL and OPG gene expression in the initial systemic lupus erythematosus patients. Chinese Journal of Osteoporosis2009; 1: 36–39.
50.
BonfáACSeguroLPCaparboVBonfáEPereiraRM. RANKL and OPG gene polymorphisms: Associations with vertebral fractures and bone mineral density in premenopausal systemic lupus erythematosus. Osteoporos Int2015; 26: 1563–1571.
